Neuromuscular expert Matthew Alexander, PhD, explores the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.:
Source: Neurology Read More
From Fibrosis to Function: Exploring New Pathways in Muscular Dystrophy Research
Related Posts
<![CDATA[FDA AdComm Votes Against Recommending
Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in
AD, Salanersen’s FDA Breakthrough Designation
Meaning]]>
<![CDATA[FDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen’s FDA Breakthrough Designation Meaning]]>
